Instalab
logoInstalab

Stemphylium Botryosum Mold IgE

See whether a hidden mold may be driving your asthma or year-round congestion when standard panels look incomplete.

Should you take a Stemphylium Botryosum Mold IgE test?

This test is most useful if any of these apply to you.

Living With Hard-to-Control Asthma
This test can uncover a mold trigger driving your asthma when standard panels have come back unhelpful or incomplete.
Year-Round Nasal Symptoms
If your congestion or runny nose persists across seasons, this can flag an indoor mold sensitization worth investigating.
Exposed to Damp or Water-Damaged Spaces
If you live or work in a building with moisture issues, this test reveals whether your immune system is reacting to common indoor molds.
Already Sensitized to Alternaria
If you know you react to Alternaria, this maps how broadly your immune system reacts across the related mold family.

About Stemphylium Botryosum Mold IgE

If you have asthma, year-round nasal symptoms, or unexplained respiratory flare-ups indoors, mold sensitization may be part of the picture. Many basic allergy panels test only a handful of common molds, which means a real trigger can sit hidden in the data.

Stemphylium IgE checks one of those less commonly tested molds. Because Stemphylium shares its main allergen with Alternaria, a positive result also flags membership in a broader family of mold sensitivities that often travel together.

What This Test Actually Detects

The test measures Stemphylium botryosum IgE, an immunoglobulin E antibody (a type of allergy antibody your immune system produces) that specifically recognizes proteins from this mold. IgE antibodies are made by B cells, a type of white blood cell, and they sit on mast cells throughout your airways and skin. When you breathe in a mold protein your IgE recognizes, the mast cells release histamine and other chemicals that drive allergy symptoms.

A positive result means your body has produced antibodies against Stemphylium and is technically sensitized. Sensitization is not the same as a clinical allergy. Some people with detectable IgE never develop symptoms, while others react strongly. Your symptom history, exposure pattern, and the size of the antibody response together determine whether the sensitization is clinically meaningful.

The Cross-Reactivity Story

Stemphylium botryosum belongs to a fungal family called Pleosporaceae, which also includes Alternaria alternata and Ulocladium botrytis. These molds share a major allergenic protein called Alt a 1. In a Spanish study of mold-sensitized patients with rhinitis or asthma, an Alt a 1-like protein was detected in Stemphylium extract and was recognized by IgE in every sensitized patient tested.

What this means in practice: if you test positive for Stemphylium IgE, your immune system is likely reacting to allergens shared across this whole mold family, not just to Stemphylium itself. The same protein that triggers your response may exist in Alternaria growing in damp basements, on stored food, or on outdoor crops in late summer and fall.

What Elevated Levels Suggest

Sensitization to molds in this family has been linked to allergic rhinitis (year-round or seasonal nasal symptoms) and asthma. In a study of asthmatic children, an extended mold testing panel that included Stemphylium identified additional patients with mold-specific IgE that a smaller standard panel had missed. Stemphylium was useful for flagging children with sensitization to seven or more different molds, a pattern associated with more difficult-to-control respiratory disease.

Sensitization to the broader Alternaria-related family has also been associated with more severe asthma in the published literature. The clinical takeaway: a clearly positive Stemphylium IgE in someone with respiratory symptoms is worth investigating, especially if a standard mold panel did not turn up an obvious trigger.

Reference Ranges

These cutpoints come from the standard ImmunoCAP-style specific IgE assay used by most reference laboratories. They are general orientation, not strict diagnostic targets. Cross-reactivity within the Pleosporaceae family means a low-positive Stemphylium result may primarily reflect sensitization to Alternaria, so always interpret your number alongside other mold IgE results and your symptoms.

ClassRange (kU/L)What It Suggests
NegativeLess than 0.10No detectable sensitization
Borderline0.10 to 0.34Very low antibody levels, clinical meaning uncertain
Class 10.35 to 0.69Low positive, possible sensitization
Class 20.70 to 3.49Moderate positive, sensitization likely
Class 3 and above3.50 or higherStrong positive, sensitization clearly present

Compare your results within the same lab over time for the most meaningful trend. Different assays and different labs can produce slightly different numbers from the same blood sample.

Tracking Your Trend

A single specific IgE reading is a snapshot. Levels can shift with seasonal exposure, recent illness, and the effect of any treatments. Tracking the trend matters more than fixating on one value, because a clear rise or fall over time tells you whether your immune system is becoming more reactive to this mold or settling down.

A reasonable cadence is to get a baseline now, retest in 3 to 6 months if you are pursuing remediation or starting allergen-targeted therapy, and then at least annually if you have respiratory symptoms or known mold exposure. If you live somewhere with a clear mold season, retesting at the same time of year removes one source of variability.

What to Do With an Elevated Result

An isolated positive Stemphylium IgE in someone with no symptoms generally does not require treatment. The decision pathway changes when the result is paired with respiratory or skin symptoms.

  • Pair it with related mold IgE tests: Alternaria, Cladosporium, and Aspergillus IgE help map the full pattern of fungal sensitization. Total IgE and an eosinophil count add context about overall allergic activity.
  • Investigate your environment: Indoor moisture, water damage, and visible mold are the most actionable exposures. Outdoor Pleosporaceae molds peak in late summer and fall, especially around grain, hay, and decaying plant matter.
  • See an allergist if symptoms persist: A specialist can confirm clinical relevance with skin prick testing or, in some cases, a controlled challenge, and discuss whether allergen immunotherapy is appropriate. Most mold immunotherapy uses Alternaria extracts, which target the shared Alt a 1 allergen.
  • Consider a workup for mold-driven lung disease if you have severe asthma, recurrent infections, or unusual lung imaging. Specialist guidelines recommend screening for fungal sensitization in adults with asthma that is hard to control.

When Results Can Be Misleading

Specific IgE detects sensitization, not symptomatic allergy. Many people have measurable antibodies without ever having a clinical reaction, which is one reason results should always be interpreted alongside symptoms and exposure history.

  • Cross-reactivity: A positive Stemphylium IgE may largely reflect antibodies to the shared Alt a 1 protein found in Alternaria. The test cannot fully separate species-specific from cross-reactive responses.
  • Recent biologic therapy: Treatment with anti-IgE antibodies such as omalizumab can change measured IgE values, including allergen-specific results, so timing of testing relative to dosing matters.
  • Assay variability: Different labs use different methods and standards. A small numeric change between labs may not represent a real biological shift.
  • Clinical context: Sensitization without symptoms does not require treatment. The number on its own is not a diagnosis.

What Moves This Biomarker

Evidence-backed interventions that affect your Stemphylium Botryosum Mold IgE level

↓ Decrease
Omalizumab, an anti-IgE antibody injection
Omalizumab binds free IgE in your blood and reduces overall IgE production over time, lowering allergic activity. The published evidence is for total IgE in patients with allergic asthma, not Stemphylium-specific IgE. By extension, allergen-specific IgE values measured during omalizumab therapy can be affected, which is why timing of allergy testing matters when this drug is being used. Omalizumab is reserved for moderate to severe allergic disease, not isolated mold sensitization.
MedicationStrong Evidence
↓ Decrease
Allergen immunotherapy targeting the Alt a 1 protein
Allergen immunotherapy retrains your immune system to react less aggressively to mold proteins, often reducing symptoms within a year. The direct evidence comes from a randomized trial of subcutaneous immunotherapy with the Alt a 1 protein from Alternaria, which significantly reduced symptoms and rescue medication use in patients with allergic rhinoconjunctivitis after 1 year. Because Stemphylium carries an Alt a 1-like protein recognized by the same antibodies, this therapy targets the shared allergen rather than Stemphylium specifically. The trial measured clinical symptoms and Alternaria IgE, not Stemphylium IgE directly.
MedicationModerate Evidence

Frequently Asked Questions

References

10 studies
  1. Moreno a, Pineda F, Alcover J, Rodriguez D, Palacios R, Martinez-naves EAllergy, Asthma & Immunology Research2016
  2. Lopez Couso VP, Tortajada-girbes M, Rodriguez Gil D, Martinez Quesada J, Palacios Pelaez RJournal of Fungi2021
  3. Celakovska J, Vankova R, Bukac J, Cermakova E, Andrys C, Krejsek JJournal of Fungi2021